Efficacy and Safety CVI, Study 2, (A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial (CVI)
This study has been completed.
Sponsor:
Boehringer Ingelheim Pharmaceuticals
Information provided by:
Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00292435
First received: February 15, 2006
Last updated: May 18, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To determine efficacy and safety of Antistax 360 mg tablets in chronic venous insufficiency linked o edema (swelling) and subjective symptoms
| Condition | Intervention | Phase |
|---|---|---|
|
Venous Insufficiency |
Drug: Read vine leaf extract (AS 195) |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind |
| Official Title: | A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax Film-coated Tablets, 360 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency. |
Further study details as provided by Boehringer Ingelheim Pharmaceuticals:
Eligibility Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00292435
Locations
| Austria | |
| LKH Graz | |
| Graz, Austria | |
| AKH Wien | |
| Wien, Austria | |
| VENEX Venenexperten | |
| Wien, Austria | |
| Czech Republic | |
| Boehringer Ingelheim Investigational Site | |
| Brno, Czech Republic | |
| Neurology-geriatric Institute | |
| Moravsky Beroun, Czech Republic | |
| Germany | |
| Boehringer Ingelheim Investigational Site | |
| Berlin, Germany | |
| Klinik und Poliklinik der Universitat Bonn | |
| Bonn, Germany | |
| Boehringer Ingelheim Investigational Site | |
| Freiburg, Germany | |
| Klinik und Poliklinik fur Hautkrankheiten | |
| Greifswald, Germany | |
| Boehringer Ingelheim Investigational Site | |
| Koln, Germany | |
| Klinikum der Johannes Gutenberg-Universitat | |
| Mainz, Germany | |
| Gesundheitszentrum Minden | |
| Minden, Germany | |
| Boehringer Ingelheim Investigational Site | |
| Munchen, Germany | |
| Boehringer Ingelheim Investigational Site | |
| Oberkirch, Germany | |
| Boehringer Ingelheim Investigational Site | |
| Rottweil, Germany | |
| Universitats-Hautklinik | |
| Tubingen, Germany | |
Sponsors and Collaborators
Boehringer Ingelheim Pharmaceuticals
Investigators
| Study Chair: | Boehringer Ingelheim Study Coordinator | Boehringer Ingelheim Pharmaceuticals |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00292435 History of Changes |
| Other Study ID Numbers: | 1138.10 |
| Study First Received: | February 15, 2006 |
| Last Updated: | May 18, 2012 |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Additional relevant MeSH terms:
|
Venous Insufficiency Vascular Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on May 23, 2013